BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
June 29, 2021 13:58 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Jafron Biomedical Announces Global Advisory Board
June 21, 2021 07:00 ET
|
Jafron Biomedical Co.,Ltd.
ZHUHAI, China, June 21, 2021 (GLOBE NEWSWIRE) -- Jafron Biomedical, a pioneer in the blood purification industry, announced it's founding the Global Advisory Board, which includes the world’s top...
HelixBind Awarded $3MM NIH Grant to Support Testing of Its RaPID Diagnostic Platform for Invasive Infections Associated with Sepsis
June 17, 2021 08:30 ET
|
HelixBind
BOXBOROUGH, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
Global Bloodstream Infection Testing Market to Garner a Revenue of $7,722.2 Million, Growing at a CAGR of 8.4% during 2019-2027 - [247 Pages] Absolute Report by Research Dive
March 24, 2021 09:45 ET
|
Research Dive
New York, USA, March 24, 2021 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global bloodstream infection testing market is forecasted to garner a revenue of $7,722.2...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
September 03, 2020 21:42 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test
August 24, 2020 11:47 ET
|
HelixBind
BOXBOROUGH, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
HelixBind Awarded $3MM Grant from NIH and Expands Clinical Advisory Board to Accelerate Development of Its Diagnostic Platform for Invasive Infections
June 10, 2020 10:29 ET
|
HelixBind
BOXBOROUGH, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies
March 04, 2020 09:56 ET
|
Arch Biopartners
TORONTO, March 04, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it is expanding the dose range of Metablok...
UPMC receives $3.7 million PCORI award to improve care for patients with sepsis and pneumonia
February 19, 2020 08:00 ET
|
UPMC Health Plan
Pittsburgh, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Today the UPMC Center for High-Value Health Care, a nonprofit research organization housed within UPMC Insurance Services, announced it has been...
Accelerate Diagnostics to Review Second Quarter 2018 Results on August 6th
July 19, 2018 14:30 ET
|
Accelerate Diagnostics, Inc.
TUCSON, Ariz., July 19, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today it will host a conference call on Monday, August 6, 2018 to review the company’s second quarter 2018...